Pharmacovigilance in Turkmenistan in 2026: MAH Guide

Updated 15 July 2026. Pharmacovigilance in Turkmenistan is governed by national medicines legislation and subordinate requirements of the Ministry of Health and Medical Industry. Turkmenistan is not an EAEU Member State, so EAEU pharmacovigilance rules do not automatically apply to Turkmen marketing authorisations.

Because detailed public procedures are limited, a marketing authorisation holder (MAH), manufacturer or local representative should confirm current requirements directly with the competent authority during registration, dossier variations and post-authorisation oversight.

Authority and legal framework

State regulation is performed by the Ministry of Health and Medical Industry of Turkmenistan and the authorised body for medicines provision.

• The Law of Turkmenistan on Medicines Provision of 12 January 2016 establishes the legal and organisational framework for medicine circulation.
• The Law assigns the authorised body responsibility for developing the procedure for monitoring adverse effects of medicines.
• The competent authorities perform marketing authorisation and control quality, safety and efficacy, and may act when a risk is identified.
• Specific forms, timelines and reporting channels should be checked against current national documents and product-authorisation conditions.

Practical MAH responsibilities

Local system and responsible person

Even where a public national document does not use GVP or PSMF terminology, the MAH should maintain a documented system, assign responsible persons and provide a local safety-reporting channel. Contacts, back-up arrangements, division of duties and cooperation with the representative or distributor should be documented.

Case intake and assessment

Processes should cover reports from healthcare professionals, patients, partners and other sources, minimum-criteria validation, medical assessment, follow-up, duplicate detection and timely submission to the competent authority in the applicable format.

Literature and regulatory monitoring

Monitoring frequency should support timely detection and reporting. Neither a universal weekly frequency nor absence of an obligation should be claimed without an official basis. Sources, languages, search criteria, results and product applicability should be documented.

Aggregate assessment, signals and risks

The MAH should maintain global benefit-risk evaluation, review signals and determine whether product information, the dossier or risk-minimisation measures require revision. Product-specific requirements for periodic reports and Risk Management Plans should be confirmed with the authority.

Oversight of the local partner

1. Establish one local safety-reporting channel.
2. Train distributor, medical-representative and quality staff.
3. Define data-exchange timelines in a safety agreement.
4. Reconcile cases regularly and document the outcome.
5. Monitor complaints, medical information and digital channels.
6. Maintain translations and an archive of regulatory submissions.
7. Verify current national requirements before every regulatory action.

Conclusion

Pharmacovigilance in Turkmenistan in 2026 requires a national, product-specific approach. Unverified statements that a PSMF, responsible person, PSUR, RMP or signal management is “not required” create regulatory risk. A documented safety system and advance confirmation of format and timelines are the safer approach.

PharmExpert supports MAHs with local partner oversight, case processing, literature and regulatory monitoring, aggregate safety assessment, safety agreements, audits and document preparation in Turkmenistan.

Official sources

1. Law of Turkmenistan on Medicines Provision.
2. Ministry of Health and Medical Industry of Turkmenistan.
3. WHO pharmacovigilance and medicine safety.

This article provides general information only. Because detailed public procedures are limited, obtain current confirmation from the competent authority before taking regulatory action.